(From left) Professor Rick Wong, Professor John Leong, Mr Ji Zhengkun, Mr Yu Wenming, Dr Constance Chan, Miss Janet Wong and Professor Lu Aiping officiate at the opening ceremony of the 2014 International Summit on Innovative Drug Discovery


(左起) 黃偉國教授、梁智仁教授、紀正昆先生、于文明先生、陳漢儀醫生、王榮珍女士和呂愛平教授為「國際中藥創新藥物研發高峰論壇2014」主持開幕典禮

Date: 10 Nov 2014 (Monday)

Archive

HKBU hosts 2014 International Summit on Innovative Drug Discovery

浸大舉辦國際中藥創新藥物研發高峰論壇2014

The School of Chinese Medicine held the 2014 International Summit on Innovative Drug Discovery on Saturday (8 November). With a focus on "Charting the Course of Standardisation of Chinese Materia Medica", the Summit featured experts and committee members of pharmacopoeias of China, USA, Europe, Australia, Japan and Hong Kong who shared their expert knowledge and insights on the standardisation of Chinese materia medica, a prerequisite for the internationalisation of Chinese medicine.

Officiating at the opening ceremony were Mr Yu Wenming, Vice-Commissioner of State Administration of Traditional Chinese Medicine, People's Republic of China; Mr Ji Zhengkun, President of China Association for Standardisation, Former Administrator of Standardisation Administration of China; Dr Constance Chan, Director of the Department of Health, HKSAR Government; Miss Janet Wong, Commissioner for Information and Technology, HKSAR Government; Professor John Leong, Chairman of the Hospital Authority, HKSAR; Professor Rick Wong, Vice-President (Research & Development); and Professor Lu Aiping, Dean of the School of Chinese Medicine.

In his opening remarks, Professor Rick Wong said that despite the robust growth of the Chinese medicine pharmaceutical industry in Mainland China, it lacks effective quality assurance systems resulting in hurdles to the production of Chinese medicinal products of high and stable quality. The task ahead is therefore to establish a system of standards for Chinese medicines to integrate Chinese medicine with modern science. He added that SCM, as one of the main tertiary institutions offering Chinese medicine education in Hong Kong, has innovative drug discovery as one of its research focuses and has been making considerable efforts to contribute to the standardisation of Chinese materia medica.

SCM launched in 2012 the biennial summit on novel drug discovery in Chinese medicines to provide a platform for scholars and experts in the field from around the world to conduct exchanges and share their latest research findings.

At the summit, Professor Rudolf Bauer, Institute of Pharmaceutical Sciences, TCM Research Center Graz, Universitaet Graz, Austria, introduced European monographs for quality control of herbal medicines; Dr Wang Mei, Sino-Dutch Centre for Preventive and Personalised Medicine, Leiden University, The Netherlands, delivered a talk on "A systems pharmacology view on Dioscorea nipponica used in modern Chinese medicine: the first traditional herbal medicinal products registered in Europe and produced in China"; Dr Richard Ko, Herbal Synergy, California, USA, provided an overview of the US approach to standardisation of traditional Chinese medicines; Professor Kelvin Chan, Faculty of Pharmacy, The University of Sydney and NICM, University of Western Sydney, introduced the global regulation and standardisation of Chinese medicines including some aspects in Australia; Dr Yukihiro Goda, Division of Drugs, National Institute of Health Sciences, Japan, gave a talk entitled "Introduction of qNMR to the Japanese Pharmacopoeia (JP) for specification of marker compounds used for standardisation of herbal medicines"; Professor Qian Zhongzhi, Chinese Pharmacopoeia Commission, gave the audience an overview of national drug standards; Professor Xiao Hongbin, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, gave a talk entitled "Preparing reference substances for herb medicine by pilot-scale - High performance column chromatography techniques"; Professor Yu Shishan, Institute of Materia Medica, Chinese Academy of Medical Sciences, shared the study on bioactive compounds with novel structures from toxic plants in China; Professor Guo De-an, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, spoke on the strategy to elaborate TCM quality monographs and global harmonisation; Professor Shen Yuandong, Shanghai Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, updated the audience on the standardisation on traditional Chinese medicine in the field of ISO (International Organisation for Standardisation) while Professor Zhao Zhongzhen, School of Chinese Medicine, HKBU, gave an talk entitled "Authentication is fundamental for standardisation and globalisation of herbal medicine".

中醫藥學院上周六(11月8日)舉辦「國際中藥創新藥物研發高峰論壇2014」,以「邁向中藥標準化之路」為主題,邀得來自中國、美國、歐洲、澳洲、日本及香港的藥典委員會成員及中藥專家,就這個與中醫藥國際化息息相關的重要課題發表他們的真知灼見。

論壇由中華人民共和國國家中醫藥管理局副局長于文明先生、中國標準化協會理事長兼國家標準化管理委員會原主任紀正昆先生、香港特區政府衞生署署長陳漢儀醫生、香港特區政府創新科技署署長王榮珍女士、香港特區醫院管理局主席梁智仁教授、浸大副校長(研究及拓展)黃偉國教授和中醫藥學院院長呂愛平教授聯合主禮。

黃偉國教授在儀式上致辭時表示,隨著中醫藥在全球漸趨普及,中國的中醫藥業近年錄得強勁的增長,但是目前仍然缺乏有效的質量保證制度,要生產穩定性和質量俱高的中醫藥產品存在一定的困難,因此當前任務是制定中藥標準,促進中醫藥與現代科學接軌。他指出,浸大中醫藥學院是香港重要的中醫教研機構,其中一個重要的研究領域是創新藥物研發,學院亦一直對促進中藥標準作出貢獻。

自2012年起,中醫藥學院每兩年舉辦一次中藥創新藥物研發高峰論壇,旨在構建一個學術平台,讓國際知名專家學者討論中藥研發的發展現狀與前景,並分享他們的最新研究成果。

在論壇上,奧地利格拉茨大學醫藥科學及藥學研究所鮑儒德教授介紹了歐洲的中藥專著;荷蘭萊頓大學中荷預防和個體化醫學中心王梅博士發表題為「對現代中藥穿龍薯蕷的系統藥理學綜述:第一個在中國生產並且在歐洲註冊成功的傳統植物藥 (tHMP)」的演講;美國加利福尼亞州Herbal Synergy公司高偉信博士概述美國對中藥標準化的思路與方法;悉尼大學藥學院及西悉尼大學國家補充醫學研究院陳金泉教授從澳洲角度窺探全球性中藥標準化和規管;日本國立醫藥品食品衞生研究所藥品部合田幸廣博士介紹日本藥局方草藥標準化;中華人民共和國國家藥典委員會錢忠直教授概說國家藥品標準;中國中醫科學院中藥研究所肖紅斌教授分享「中藥化學對照品高效、規模制備色譜柱及分離技術」;中國醫學科學院藥物研究所庾石山教授探討「有毒植物新穎結構活性化合物研究」;中國科學院上海藥物研究所果德安教授討論「中藥質量標準和全球統一策略」;上海中醫藥大學附屬曙光醫院沈遠東教授簡介國際標準化組織 (ISO) 的中藥標準化工作;浸大中醫藥學院趙中振教授則分享「中藥鑒定是中藥標準化與國際化的基礎」。